Gilead Stops Cancer Drug Trial Early On Positive Results NASDAQ Gilead said an interim analysis of the trial showed patients taking idelalisib plus rituximab with better progression-free survival compared to those receiving rituximab alone. The company said it has informed the U.S. Food and Drug Administration of ... |
